The Cheapest Semaglutide Is a Legal Question Before It Is a Price Question

In India, as of October 8, 2026, the lowest stated monthly price for generic semaglutide was 1,290 rupees (roughly $15), for vials from Natco and Eris. In the United States, the 2024 list price of Ozempic was $959 for a 30-day supply. Same molecule. The difference is not chemistry. It is mostly law.

So if you typed “cheapest semaglutide” into a search engine, the honest answer has two halves. Globally, the cheapest legal semaglutide is generic, and as of September 2026 it was on sale in India, Canada, Brazil, South Africa and Saudi Arabia. In the US no generic is on sale, and the lowest legal prices belong to the brand: Novo Nordisk’s self-pay price for Wegovy started at $149 a month for the pill and $199 a month for the pen as of October 21, 2026, and the Medicare negotiated price of $274 per 30-day supply takes effect January 1, 2027.

Where the cheapest semaglutide is sold, and why there

Novo Nordisk filed its core semaglutide compound patent on March 20, 2006. Patents last 20 years, so in markets without extensions the patent ended on March 20, 2026. In India it lapsed that day, and on March 21 more than 40 generic brands launched. Monthly prices went from 8,800 to 11,175 rupees for Ozempic (roughly $100 to $130) to 1,800 to 4,200 rupees for generics (roughly $20 to $50).

Novo noticed. Within about ten days it cut Ozempic’s Indian price by 36% and Wegovy’s by 48%. Generics still took 50% of India’s semaglutide sales by value in April 2026. Canada got there by a stranger road (a lapsed patent and an unpaid maintenance fee), which the site covers elsewhere.

In the US, the compound patent, US 8,129,343, got a 1,040-day patent term extension, pushing it to December 5, 2031. Novo’s 2025 Form 20-F says 2032 is the effective compound expiry for Ozempic, Rybelsus and Wegovy, and secondary patents run to 2038. I would rather not think too hard about what the patent lawyers have scheduled for the years between 2032 and 2038.

The legal routes that exist in the US today

There are not many, and they all run through the patent holder or the government. One is the brand’s own self-pay price, the $149 and $199 figures above. Another is Medicare, which put Ozempic, Rybelsus and Wegovy into the second round of drug price negotiation under the Inflation Reduction Act. The result is $274 per 30-day supply, which is a 71% reduction from the $959 list price. That is a big number delivered in a federal register sort of voice (which is the only voice the federal register has, and it uses it for everything).

Then there is compounding, where US pharmacies sold injectable semaglutide for an average of $230 a month, and where industry groups won court injunctions that, in the words of one legal explainer, “temporarily prevented a complete shutdown” of FDA enforcement against 503B outsourcers. That is a different site’s subject, and also a different legal theory (compounding is not generic entry, and nobody involved pretends it is).

The generic that is approved and also not allowed

On April 10, 2026, Apotex announced the first FDA tentative approval for a generic version of Ozempic, in partnership with Orbicular. Here is what that means in plain words: the FDA looked at the drug, decided it was fine, and told Apotex it may not sell it. That is tentative approval (an extremely bureaucratic form of congratulations). It means the science is done and the patents are not.

The machinery behind this is the Hatch-Waxman Act of 1984, which created both the patent term extension that stretched semaglutide’s patent and the system where a brand company that lists patents in the FDA’s Orange Book can trigger an automatic 30-month stay on generic approval. In some sense the same law gives with one hand and waits with the other. That’s fine; it was designed as a bargain.

Here is a scenario I am making up entirely. A generic company with a tentative approval assigns one employee to watch the calendar. Her whole job is to walk into the CEO’s office every Monday and say “Good news, still approved. Bad news, still 2031.” She does this for five years. She gets a promotion for consistency. She trains a successor, who also watches the calendar, and by December 2031 the company has a small department whose only output is the date. It is like a studio announcing a movie release slot six years out and then hiring people to stare at the poster.

How to read a price that is too good

Between us, this is the part that matters to anyone staring at a web page with a number on it. The legal US reference points are roughly $149 to $274 a month from the brand and the government, and around $230 on average from compounders. No FDA-approved generic semaglutide is on sale in the US, because the patents have not ended. So any US listing for “generic semaglutide” is describing something other than an approved, launched generic, whatever it calls itself.

The overseas prices are real, but they are prices under Indian or Canadian law, or whatever law applies where the drug is sold. Whether those products can lawfully reach a US buyer is not something the facts here settle, and it is not settled by a low number either.

There is also a ceiling on how cheap legal generics tend to get in America. Prost Biotech notes that US peptide generics typically see only 15% to 40% discounts, versus 80% to 90% for small-molecule generics, “due to the more expensive biosimilar approval pathway.” When Teva launched generic Victoza, it priced a two-pack at $469.60 against roughly $560 for the brand. That’s 16% to 17% off. Even in 2026, with more companies selling it, the average GoodRx price for Teva’s generic liraglutide ran $200 to $450 for a two-pen package and $280 to $750 for a three-pen package. That is what a real, approved, launched US peptide generic looks like on a price page. A US price that beats the brand by 95% is presumably not following that history.

Three ways to read the gap

There are, roughly, three ways to read the distance between $15 in India and $959 in America.

The first is the patent reading. Price is a function of which calendar you live under. India’s patent ended March 20, 2026, and generics launched March 21. The molecule did not change overnight. The permission did.

The second is the competition reading, where prices fall when the brand feels pressure, not only when generics arrive. Novo cut Wegovy’s Indian price by up to 37% in November 2025, before expiry, and then cut the starting dose by 48% on April 1, 2026. FDA data show generic prices about 39% below brand with one generic producer and more than 95% below with six or more. Brazil just writes it down: the OzemPro Blog says generics there “must be sold at least 35% below the reference product’s price.” Market conditions move both ways, of course. Pharmaceutical Technology reported that Eli Lilly raised the UK price of Mounjaro to “better reflect market conditions,” which is the same sentence pointed in the other direction, lol.

The third reading is the least comfortable. A systematic literature review found prices falling 34% to 93.4% in the one to five years after patent expiry, with lots of variation. Medicare’s negotiation already took 71% off before any generic exists. If US peptide generics land at their usual 15% to 40% discount off a list price, they may arrive in 2032 to find the government got there first. I mean, the stuff about patent cliffs assumes the cliff is the bottom. Anyway, the cheapest legal semaglutide in America, for the foreseeable future, may keep being sold by the company whose patent is the reason it isn’t cheaper.